Hypofractionated Definitive Chemoradiotherapy for Oesophageal Cancer

The goal of this clinical trial is to learn if hypofractionation of definitive chemoradiotherapy can treat patients with locally advanced esophageal cancer. The main question it aims to answer is if this treatment is feasible and safe. We also want to investigate the toxicity, in particular the radiation-induced lymphopenia. Normally, definitive chemoradiotherapy for patients with locally advanced esophageal cancer consist of 28 fractions of 1.8 Gy with concurrent 6 cycles of carboplatin and paclitaxel in 5.5 weeks. In this study, participants will receive 20 fractions of 2.4 Gy with concurrent 6 cycles of carboplatin and paclitaxel in 4 weeks. The follow-up will be conform standard-of-care.

NCT Number	NCT07632079
Lead Sponsor	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Collaborators: University Medical Center Groningen
Conditions	Locally Advanced Esophageal or GE Junction Cancer
Enrollment	60 participants
Start Date	2026-04-28
Primary Completion	2028-04 (estimated)
Study Completion	2028-07 (estimated)
Updated on ClinicalTrials.gov	2026-06-08